Primus In News
Sun Pharma partner withdraws EU application for skin cancer drug
26-06-2025
Nilaya Varma, Co-founder and Group CEO, Primus Partners, highlighted that Philogen’s withdrawal of the EU marketing application for Nidlegy marks an untimely setback for Sun Pharma. While it may not have immediate financial implications, it poses risks to the company’s long term strategic presence in Europe and Australia. This development follows closely on the heels of another disappointment as SCD44's failure triggered an 18% drop in Sun Pharma’s stock earlier this month.
Explore Related Insights
- Fighting cyber crimes: How much control should the government have on the internet?
- Banks must push RBI’s 15K cr liquidity for “contact intensive sectors”: Experts
- Car sales jolted by subdued demand in June 2025; Maruti, Hyundai, Tata take hit
- Lasik surgery market to double by 2030 amid rising myopia, tech advances